Clinical trial: Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541444)
The combination of venetoclax with cytarabine and daunorubicin or venetoclax with azacitidine is being evaluated for improved outcomes in newly diagnosed AML patients compared to standard cytarabine + daunorubicin.
This open‑label, single‑arm, Phase I‑III study aims to assess the safety and efficacy of allogenic NK cells that have been genetically engineered via AccuBase™ base editor to knock out PD‑1 and knock‑in CD16. NK cells will be infused once a week; investigators will monitor dose‑limited toxicity, determine maximum tolerated dose, and provide dosing guidance for future trials.
Patients with relapsed or refractory AML have limited treatment options and poor prognosis. Gene‑edited NK cells that lack PD‑1 inhibitory signals and express CD16 to enhance antibody‑dependent cellular cytotoxicity may offer a novel, potentially curative immunotherapy approach for this high‑need patient population.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Management of Acute Myeloid Leukemia: A Review
- Old cells, new tricks—important clue to AML diagnosis and cure discovered
- Treatment of Acute Myeloid Leukaemia
- Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates
- Research blog: Accelerating progress in AML